Table 3.

Ex vivo longitudinal profiling of EBV-specific T-cell responses in HL patients and healthy individuals using ELISPOT assays

EBV antigen, patient groupNo. of assaysMean SFCs (SE)*Median SFCs (IQR)*P vs pretherapyP vs 6 moP vs 12 moP vs long-term remission
LMP1/2A
    ND/RL pretherapy 87 30 (8) 0 (0-24)
    ND/RL 6 mo 45 87 (24) 0 (0-106) .091
    ND/RL 12 mo 41 101 (25) 27 (0-169) .014 .494
    Long-term remission 136 153 (33) 30 (0-176) < .001 .07 .387
    Healthy 41 102 (40) 32 (0-94) .002 .329 .996 .442
EBNA3/4/6
    ND/RL pretherapy 33 221 (77) 58 (0-187)
    ND/RL 6 mo 21 149 (42) 60 (40-178) .651
    ND/RL 12 mo 24 351 (93) 135 (8-135) .190 .311
    Long-term remission 39 290 (74) 106 (14-106) .258 .582 .645
    Healthy 43 186 (54) 60 (0-195) .941 .621 .144 .247
Lytic
    ND/RL pretherapy 16 235 (63) 175 (0-476)
    ND/RL 6 mo 10 389 (165) 128 (49-916) .6
    ND/RL 12 mo 13 631 (161) 506 (35-1187) .076 .515
    Long-term remission 23 304 (78) 194 (80-294) .568 .71 .122
    Healthy 6 245 (51) 254 (116-367) .606 .492 .237 .536
  • SE indicates standard error; IQR, interquartile range; —, not applicable.

  • * Arithmetic mean and median values of γ-interferon—producing cells (referred to as spot-forming cells [SFCs] per 106 PBMCs) in response to HLA class 1—restricted LMP1/2, EBNA3/4/6, and lytic antigen peptide epitopes.

  • Significant P value.